FLNA; filamin A, alpha; ABP-280; ABPX; CVD1; FLN; FLN-A; FLN1; FMD; MNS; NHBP; OPD; OPD1; OPD2; XLVD; XMVD; actin binding protein 280; alpha-filamin; endothelial actin-binding protein; filamin-1; filamin-A; non-muscle filamin; FLNA antibody; filamin A; alpha antibody; ABP-280 antibody; ABPX antibody; CVD1 antibody; FLN antibody; FLN-A antibody; FLN1 antibody; FMD antibody; MNS antibody; NHBP antibody; OPD antibody; OPD1 antibody; OPD2 antibody; XLVD antibody; XMVD antibody; actin binding protein 280 antibody; alpha-filamin antibody; endothelial actin-binding protein antibody; filamin-1 antibody; filamin-A antibody; non-muscle filamin antibody; Filamin A; filamin A (aa662-676)

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Goat

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul (lot specific)

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Manufactured in an ISO 9001:2008 Certified Laboratory.

Small volumes of anti-FLNA antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Peptide ELISA (EIA), Western Blot (WB)

Peptide ELISA: Antibody detection limit dilution 1: 128000.
Western Blot: Approx 250kDa band observed in Human Uterus lysates (calculated MW of 281kDa according to NP_001447.2). Recommended concentration: 0.1-0.3ug/ml.

(0.1ug/ml) staining of Human Uterus lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

280,018 Da

filamin A

filamin-A

Filamin-A

FLN; FLN1; FLN-A; ABP-280??[Similar Products]

FLNA_HUMAN

The protein encoded by this gene is an actin-binding protein that crosslinks actin filaments and links actin filaments to membrane glycoproteins. The encoded protein is involved in remodeling the cytoskeleton to effect changes in cell shape and migration. This protein interacts with integrins, transmembrane receptor complexes, and second messengers. Defects in this gene are a cause of several syndromes, including periventricular nodular heterotopias (PVNH1, PVNH4), otopalatodigital syndromes (OPD1, OPD2), frontometaphyseal dysplasia (FMD), Melnick-Needles syndrome (MNS), and X-linked congenital idiopathic intestinal pseudoobstruction (CIIPX). Two transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Mar 2009]

FLNA: a ubiquitous cytoskeletal protein that promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Plays an essential role in embryonic cell migration. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interactions with filamin A may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking.

Protein type: Motility/polarity/chemotaxis; Nuclear receptor co-regulator; Actin-binding

Chromosomal Location of Human Ortholog: Xq28

Cellular Component: actin cytoskeleton; cell soma; cortical cytoskeleton; cytoplasm; cytosol; dendritic shaft; extracellular region; filamentous actin; focal adhesion; intercellular junction; membrane; nucleolus; nucleus; perinuclear region of cytoplasm; plasma membrane

Molecular Function: actin filament binding; G-protein-coupled receptor binding; glycoprotein binding; GTPase binding; kinase binding; mu-type opioid receptor binding; protein binding; protein homodimerization activity; Rac GTPase binding; Ral GTPase binding; Rho GTPase binding; signal transducer activity; SMAD binding; small GTPase binding; transcription factor binding

Biological Process: actin crosslink formation; actin cytoskeleton reorganization; cilium biogenesis; cytoplasmic sequestering of protein; dopamine receptor, adenylate cyclase inhibiting pathway; establishment of protein localization; mRNA transcription from RNA polymerase II promoter; negative regulation of apoptosis; negative regulation of protein catabolic process; negative regulation of transcription factor activity; negative regulation of transcription from RNA polymerase I promoter; platelet activation; platelet degranulation; positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of transcription factor import into nucleus; protein stabilization; receptor clustering; regulation of cell migration

Disease: Cardiac Valvular Dysplasia, X-linked; Fg Syndrome 2; Frontometaphyseal Dysplasia; Heterotopia, Periventricular, Ehlers-danlos Variant; Heterotopia, Periventricular, X-linked Dominant; Intestinal Pseudoobstruction, Neuronal, Chronic Idiopathic, X-linked; Melnick-needles Syndrome; Otopalatodigital Syndrome, Type I; Otopalatodigital Syndrome, Type Ii; Terminal Osseous Dysplasia

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.